Posted by Michael Wonder on 03 Dec 2020
Secukinumab in children with plaque psoriasis: study unsuitable for benefit assessment
3 December 2020 - Inappropriate treatment in the control arm makes fair comparison impossible.
The monoclonal antibody secukinumab is approved for the treatment of children and adolescents aged six years and over with moderate to severe plaque psoriasis for whom systemic therapy is an option. In an early benefit assessment, the Institute for Quality and Efficiency in Health Care (IQWiG) has now examined whether the active ingredient offers these patients an additional benefit compared to the appropriate comparator therapy .
Since Novartis did not adequately treat the participants in the control arm of the study on which his dossier is based, a fair comparison is not possible. The conclusion is therefore: an additional benefit has not been proven.
